TSO3 Inc

TSO3 — Investor Presentation (May 2017)

31 slides from TSO3's investor presentation, May 2017

  1. Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing

    TSX:TOS To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation May 2017

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certa

  3. Slide 3: TSO3 - Our Vision

    TSO3 - Our Vision TSX:TOS To Create and Deliver the New Standard of Care in Sterile Reprocessing™ 3

  4. Slide 4: Company Milestones

    Company Milestones TSX:TOS 2016  Shipped 110 STERIZONE® VP4 Sterilizers  Secured significant P.O. for 2017 shipments 2009 - 2014  Record revenues & assembly capacity  Reworked products  US$19.6M in cash1 1998  Introduced STERIZONE®  Extended FDA claims to include 125L+ and VP4 Sterilizers col

  5. Slide 5: Purpose

    Purpose TSX:TOS A Sterile Device for Every Procedure 5

  6. Slide 6: The Science – Patents or Patents Pending

    The Science – 47 Patents or Patents Pending TSX:TOS Half-Cycle 1 Half-Cycle 2 Pressure 1000 (Torr) Atmosphere 100 20 10 1 Dynamic Dynamic H2O2 H2O2 Time Exposure Exposure Pre- H2O2 Evacuation H2O2 Evacuation Ventilation conditioning Reduction Reduction Phase 1 Phase 2 6

  7. Slide 7: Create and Control a Micro-Condensation Event

    Create and Control a Micro-Condensation Event TSX:TOS Dynamic Delivery System™ A relatively cool device in a warm humid environment 7

  8. Slide 8: Central Sterilization (OR Support)

    Central Sterilization (OR Support) 8

  9. Slide 9: Existing Sterilization Equipment Market

    Existing Sterilization Equipment Market TSX:TOS Global Sterilization Equipment Market3  LT Sterilization is fastest growing ($ billions) sterilization segment (9-10% CAGR)1 $6.9B  Estimated equipment replacement value $6.4B $5.9B approximately $4.5 billion2 $5.5B $5.1B $4.7B  ~30,000 units global

  10. Slide 10: Growing Demand for MIS & Endoscopy Procedures

    Growing Demand for MIS & Endoscopy Procedures TSX:TOS Aging Recovery Bed Time Minimally Invasive Surgeries Population Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries & Endoscopies Growth in U.S. Population Age Groups 65+2 More than 30 million 85+ MIS procedur

  11. Slide 11: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim - Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free Proprietary Technology automatically cycle selection adjusts the st

  12. Slide 12: Improving Existing LT Sterilization Practice

    Improving Existing LT Sterilization Practice TSX:TOS Old Technology TSO3 Technology • 20+ year-old core technology  Next generation industry technology • Single sterilant  Dual Sterilant • Fixed delivery  Dynamic Delivery • Time consuming, complex procedures  Simple Single Cycle Operation • Oper

  13. Slide 13: Chamber Load Capacities

    Chamber Load Capacities TSX:TOS Competitive Comparison of a Typical Flexible Endoscope Load VS 13

  14. Slide 14: GI Market

    GI Market +, 14

  15. Slide 15: GI Endoscopy Market

    GI Endoscopy Market TSX:TOS  Greenfield opportunity for Terminal Endoscopic Procedures in Europe and US1,2 Sterilization – displacing HLD (millions)  Potential to terminally sterilize far more of 75M the 55m+ annual endoscopies1 (US & Europe) 55M  Nearly 50% are colonoscopies – none of which are

  16. Slide 16: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing TSX:TOS Old Technology TSO3 Technology • Typically high level disinfection  Sterilization not high level disinfection • A fundamentally inferior level of  Far higher degree of certainty certainty • Many contaminated scopes  The only FDA-cleared technology val

  17. Slide 17: The Problem: Endoscopes & Superbugs

    The Problem: Endoscopes & Superbugs TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic-resistant bacteria annually – 23,000 die1  CRE is resistant to most available antibiotics - up to 50% of infected patients die2  CRE infections growing and linked

  18. Slide 18: Call to Action

    Call to Action TSX:TOS “Despite reprocessing in accordance with US guidelines, viable microbes and Portion of Gastroscopes Meeting biologic debris persisted in clinically used [GI] endoscopes, suggesting current Cleaning Benchmarks reprocessing guidelines are not sufficient to ensure successful deco

  19. Slide 19: The Solution: FDA Clearance of Endoscope Claims

    The Solution: FDA Clearance of Endoscope Claims TSX:TOS CLEARED An Industry First: FDA has cleared the STERIZONE® VP4 Sterilizer for the sterilization of multi-channeled flexible endoscopes (with four or fewer channels) having internal lumens of ≥ 1.45 mm in July 2016: FDA cleared expanded indicatio

  20. Slide 20: Next Steps: the GI Market

    Next Steps: the GI Market TSX:TOS Duodenoscope  Expanded Claims – FDA – Duodenoscopes  Already cleared in Canada and Europe  Duodenoscope internal testing complete  Initiated testing with key ERCP OEM  Market/Industry Awareness – All Flexible Scopes  Working with US legislators on awareness ca

  21. Slide 21: Commercialization

    Commercialization 21

  22. Slide 22: Commercialization

    Commercialization TSX:TOS “The STERIZONE® VP4 Sterilizer  Getinge: Exclusive Global Distributor uniquely addresses an unmet global  Global sales & service - over 3,000 associates in 36 countries need for cost effective, high throughput  US$7.5M up front license fee sterilization of complex medica

  23. Slide 23: Commercialization

    Commercialization TSX:TOS Overview Brochure Fractional Print Ad Series Email /Mobile Email Landing Page Web Banners 23

  24. Slide 24: Commercialization

    Commercialization TSX:TOS Fractional Print Ad Series 24

  25. Slide 25: IAHCSMM, Nashville - May 2017

    IAHCSMM, Nashville - May 2017 TSX:TOS 25

  26. Slide 26: 2016 and 2017 Financial Highlights – USD

    2016 and 2017 Financial Highlights – USD TSX:TOS Quarterly Revenues  2016 and 2017 Highlights US$ Millions $4.2  2016 Revenues: $13.3M (110 units shipped) $3.7  Q1 2017 Revenues: $4.2M (36 units shipped) $3.5 $3.1 $3.0  Q1 2017 Gross margin: 37%  Installations occurring and consumables sales gr

  27. Slide 27: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All dollars in USD, unless noted otherwise TSX:TOS Stock Price (5/3/17) CAD$3.15 Total Revenue (mrq) $4.2M Cash & ST Investments (mrq) $19.6M 52 Week High-Low CAD$3.82-$2.05 Gross Profit (mrq) $1.6M Total Assets (mrq) $26.7M Avg. Daily Vol. (3 mo.) 0.15M Net Loss (mrq) $(2.0)M T

  28. Slide 28: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  Recurring Revenue Business Model with proprietary captive Global consumables Distribution Partner  Industry Changing Technology  Dual Sterilant  Dynamic Sterilant Delivery SystemTM  Addressing Large Market Opportunities  Traditional low temperature sterilization  F

  29. Slide 29: Contact Us

    Contact Us TSX:TOS TSO3 Inc. - Canada Investor Relations 2505 Dalton Avenue Québec, Québec Ron Both Managing Partner G1P 3S5 CANADA CMA Tel (949) 432-7566 Tel (418) 651-0003 TOS@cma.team info@tso3.com Barry Mire Vice President TSO3 Corporation - US Renmark Financial Communications Inc. Tel (416) 644

  30. Slide 30: Appendix

    Appendix +,

  31. Slide 31: Regulatory Progression - Endoscopes

    Regulatory Progression - Endoscopes TSX:TOS FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi-Critical Critica

TSO3 — Investor Presentation (May 2017) on 6ix